NCT07142811 - A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

August 5, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

April 30, 2031

Conditions

Viral Hepatitis

Interventions

DRUG

Tobevibart

Tobevibart administered by subcutaneous injection

DRUG

Elebsiran

Elebsiran administered by subcutaneous injection

DRUG

Bulevirtide

Bulevirtide administered by subcutaneous injection

Trial Locations (26)

1020

RECRUITING

Investigative Site, Brussels

1407

RECRUITING

Investigative Site, Sofia

1431

RECRUITING

Investigative Site, Sofia

2025

RECRUITING

Investigative Site, Chisinau

2650

RECRUITING

Investigative Site, Edegem

6003

RECRUITING

Investigative Site, Stara Zagora

30625

RECRUITING

Investigative Site, Hanover

31059

RECRUITING

Investigative Site, Toulouse

35000

RECRUITING

Investigative Site, Rennes

46000

RECRUITING

Investigative Site, Rawalpindi

54800

RECRUITING

Investigative Site, Lahore

74800

RECRUITING

Investigative Site, Karachi

75600

RECRUITING

Investigative Site, Karachi

87042

RECRUITING

Investigative Site, Limoges

92110

RECRUITING

Investigative Site, Clichy

1081 HV

RECRUITING

Investigative Site, Amsterdam

6525 GA

RECRUITING

Investigative Site, Nijmegen

3015 GD

RECRUITING

Investigative Site, Rotterdam

021105

RECRUITING

Investigative Site, Bucharest

022328

RECRUITING

Investigative Site, Bucharest

030303

RECRUITING

Investigative Site, Bucharest

08028

RECRUITING

Investigative Site, Barcelona

01135

RECRUITING

Investigative Site, Kyiv

E1 1BB

RECRUITING

Investigative Site, London

SE5 9RS

RECRUITING

Investigative Site, London

NG7 2UH

RECRUITING

Investigative Site, Nottingham

All Listed Sponsors

lead

Vir Biotechnology, Inc.

INDUSTRY